AKT3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL190637	1.00	20/20
SCHEMBL190846	1.00	20/20
SCHEMBL190978	1.00	20/20
SCHEMBL190979	1.00	20/20
SCHEMBL191072	1.00	20/20
SCHEMBL191124	1.00	20/20
SCHEMBL191125	1.00	20/20
SCHEMBL191220	1.00	20/20
SCHEMBL191438	1.00	20/20
SCHEMBL191439	1.00	20/20
SCHEMBL191446	1.00	20/20
SCHEMBL191447	1.00	20/20
Ipatasertib (SCHEMBL191491)	1.00	20/20
Ipatasertib (SCHEMBL191492)	1.00	20/20
Ipatasertib (SCHEMBL191495)	1.00	20/20
Ipatasertib (SCHEMBL191496)	1.00	20/20
SCHEMBL191553	1.00	20/20
SCHEMBL191554	1.00	20/20
SCHEMBL191650	1.00	20/20
SCHEMBL191651	1.00	20/20

Clinical trials — most relevant to AKT3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)	PHASE2	ACTIVE_NOT_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)	PHASE2	COMPLETED
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas	PHASE2	COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome	PHASE1	COMPLETED
A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a AKT3 binder may also engage these)

Protein	Name	Similarity
Q9WUA6	—	1.000	Q9WUA6 →
Q63484	—	1.000	Q63484 →
P47197	—	0.999	P47197 →
Q7ZX15	—	0.999	Q7ZX15 →
Q98TY9	—	0.997	Q98TY9 →
Q6IP76	—	0.997	Q6IP76 →
AKT2	RAC-beta serine/threonine-protein kinase	0.995	landscape →
Q60823	—	0.994	Q60823 →
P31750	—	0.992	P31750 →
AKT1	RAC-alpha serine/threonine-protein kinase	0.989	landscape →
P31748	—	0.988	P31748 →
P47196	—	0.985	P47196 →
Q01314	—	0.983	Q01314 →
Q2RAX3	—	0.972	Q2RAX3 →
Q6X4A2	—	0.970	Q6X4A2 →
Q39192	—	0.966	Q39192 →
Q2V452	—	0.964	Q2V452 →
O64812	—	0.964	O64812 →
Q91Y86	—	0.963	Q91Y86 →
Q6ZLP5	—	0.962	Q6ZLP5 →
P79996	—	0.962	P79996 →
P49185	—	0.962	P49185 →
P68182	—	0.961	P68182 →
MAPK8	Mitogen-activated protein kinase 8	0.961	landscape →
Q84VQ3	—	0.961	Q84VQ3 →
P49071	—	0.961	P49071 →
Q90327	—	0.960	Q90327 →
PRKCA	Protein kinase C alpha type	0.960	landscape →
Q2QY53	—	0.960	Q2QY53 →
Q9M9E9	—	0.960	Q9M9E9 →